Sun, T., Ouyang, Q., Shi, Y., Cai, L., Yang, J., Wang, Y., He, L., Feng, F., Yu, Y., Hao, S., Wang, X. (2026). Culmerciclib (CDK2/4/6 inhibitor) plus fulvestrant in HR+/HER2− advanced breast cancer after progression on CDK4/6i: Preliminary results from a phase II trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1082